Exploratory Biomarker Analysis of Neoadjuvant Chemoimmunotherapy Followed by Pulmonary Resection in Stage II-III Non-Small Cell Lung Cancer
Launched by YONSEI UNIVERSITY · Mar 31, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how certain biological markers in tissue and blood can help doctors understand which patients with stage II-III non-small cell lung cancer may not respond well to a type of treatment called neoadjuvant chemoimmunotherapy, which is given before surgery. The study aims to find ways to identify these patients early on and also to predict how well the treatment works before surgery by looking for specific markers in the blood.
To participate, patients must be at least 19 years old and have been diagnosed with stage II-III lung cancer, without certain genetic changes that could affect their treatment. They should generally be in good health, as assessed by their performance status. Participants will undergo evaluations and tests to help researchers gather valuable information about the disease and treatment response. This trial is currently recruiting participants, and anyone considering joining should discuss it with their doctor to understand if it’s a good fit for them.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically proven clinical stage II-III lung cancer patients
- • No driver mutations (EGFR mutation and ALK alteration)
- • Whole body performance (ECOG) 0-1
- • Those over 19 years of age
- • Subject who submitted Informed consent form
- Exclusion Criteria:
- • Under 19 years of age
- • If there is a history of causing infection or other serious medical problems that impair the patient's function and make it difficult to comply with the study protocol.
- • Patients for whom the investigator determines that the patient should not participate in the clinical trial because the patient is judged to be unable to comply with the clinical trial procedures and requirements (a person lacking medical capacity)
- • Other patients (pregnant women, etc.) determined by the clinical trial director to be unsuitable for this clinical trial.
About Yonsei University
Yonsei University, a prestigious institution located in South Korea, is renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Yonsei University leverages its extensive expertise and innovative approaches in various fields of medicine to conduct rigorous clinical trials aimed at improving patient outcomes and advancing healthcare solutions. The university's robust infrastructure, multidisciplinary collaboration, and adherence to ethical standards ensure the integrity and reliability of its research initiatives, making it a key player in the global clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported